MECOM and intrahepatic cholangiocarcinoma: Another major change introduced by both the ICC and the WHO groups is the expansion of AML-defining recurring genetic abnormalities to include t(9;11)(p21.3;q23.3)/MLLT3::KMT2A (or other KMT2A rearrangements), t(6;9)(p22.3;q34.1)/DEK::NUP214, inv(3)(q21.3q26.2)/MECOM(EVI1) (or other MECOM rearrangements) and NPM1, in-frame basic leucine zipper-region (bZIP) CEBPA mutations [114,115,116,117].